This was taken from a Cambridge Cognition messageboard. Would really like to have a second opinion here.
"Not a chance Cogstate are involved in my view. You go to Cogstate for an excellent commercial/commodity type offering. You go to COG for complex/bespoke research projects exploring leading edge ideas that require analysis and insight. With this large, multi-year, research driven project, COG would be the only commercial group qualified in my view. The reason I suspect COG are involved can be seen from looking at the linkedin page of Biogen's Matt Hobbs, who moved across from COG last year. With no disrespect intended to the excellent scientific team at Cogstate, when it comes to innovation they are not a patch on the COG team (Pam Ventola is a possible exception). For example Cogstate are still researching their voice based products and are probably still at least 24 months away from having a validated product, COG are already in the market and getting paid with their voice project. If we move on to other aspects such as wareables, social cognition, digital phenotyping etc, COG are so far ahead of Cogstate it is not even really open for debate. Where Cogstate are (have been) much stronger than COG is with commercialisation and they continue to do an excellent job at that. However their commercial focus also means they only purse areas where they can get paid at scale rather than one off bespoke projects."
- Forums
- ASX - By Stock
- Biogen and Apple study early signs of Cognitive Impairment
CGS
cogstate ltd
Add to My Watchlist
0.61%
!
$1.66

This was taken from a Cambridge Cognition messageboard. Would...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.66 |
Change
0.010(0.61%) |
Mkt cap ! $280.4M |
Open | High | Low | Value | Volume |
$1.65 | $1.68 | $1.62 | $34.96K | 21.09K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 621 | $1.61 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.68 | 2298 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 621 | 1.610 |
7 | 7699 | 1.600 |
1 | 3785 | 1.585 |
3 | 10722 | 1.575 |
1 | 829 | 1.570 |
Price($) | Vol. | No. |
---|---|---|
1.680 | 2298 | 1 |
1.710 | 10000 | 1 |
1.740 | 1000 | 1 |
1.750 | 1758 | 1 |
1.790 | 1789 | 1 |
Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
Featured News
CGS (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online